Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02718417 · ClinicalTrials.gov registry record · Phase 3
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 998
- Enrollment target
NCT02718417 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 998 participants.
The verdict
NCT02718417, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 998 participants
- Enrollment target
Study Summary
This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy. The primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance setting following frontline chemotherapy or in combination with carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by observation in this population of newly diagnosed ovarian cancer patients.
Interventions
- DRUG Avelumab
- DRUG carboplatin
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 998 participants |
| Start Date | 2016-05-19 |
| Est. Completion | 2019-05-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02718417
The ClinicalTrials.gov registry entry for NCT02718417 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 998 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Avelumab is the first listed.
NCT02718417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02718417 about?
NCT02718417 is a clinical study titled "Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)". This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer...
What is the current status of trial NCT02718417?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 998 participants. The study started on 2016-05-19. Estimated completion is 2019-05-16.
What interventions are being tested in trial NCT02718417?
The interventions under investigation include: Avelumab (DRUG), carboplatin (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02718417?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.